BA
PTLA

Boston Advisors’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Boston Advisors’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$476K Buy
+17,738
New +$498K 0.02% 464

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Boston Advisors's PTLA Position: Q3 2019 in Review

Boston Advisors opened a new position in Portola Pharmaceuticals, Inc. (PTLA) in Q3 2019: 17,738 shares worth $476K. The stake represents 0.02% of the portfolio and ranks #464 among its holdings.

212 funds tracked by Wall St. Rank hold PTLA as of Q3 2019.

  • Boston Advisors held 17,738 shares of Portola Pharmaceuticals, Inc. worth $476K as of Q3 2019.
  • Portola Pharmaceuticals, Inc. was a new Boston Advisors position in Q3 2019.
  • Portola Pharmaceuticals, Inc. made up 0.02% of Boston Advisors's portfolio in Q3 2019, its #464 holding.
  • 212 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2019.

Based on Boston Advisors's 13F filing for Q3 2019, filed 5 Nov 2019.